PE20161364A1 - CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS - Google Patents
CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSASInfo
- Publication number
- PE20161364A1 PE20161364A1 PE2016001895A PE2016001895A PE20161364A1 PE 20161364 A1 PE20161364 A1 PE 20161364A1 PE 2016001895 A PE2016001895 A PE 2016001895A PE 2016001895 A PE2016001895 A PE 2016001895A PE 20161364 A1 PE20161364 A1 PE 20161364A1
- Authority
- PE
- Peru
- Prior art keywords
- cyano
- halogen
- chromene
- methyl
- hydroxy
- Prior art date
Links
- YIOCEUUNNIKUMJ-UHFFFAOYSA-N 1,1a,2,7b-tetrahydrocyclopropa[c]chromene Chemical compound C1=CC=C2C3CC3COC2=C1 YIOCEUUNNIKUMJ-UHFFFAOYSA-N 0.000 title 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- -1 cyano, hydroxy Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- SIQJUJBSEDNWPI-UHFFFAOYSA-N CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C Chemical compound CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C SIQJUJBSEDNWPI-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MZPMUGOGQIVILU-UHFFFAOYSA-N ClC=1C=C2C(=CC(OC2=C(C1)F)(C)C)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O Chemical compound ClC=1C=C2C(=CC(OC2=C(C1)F)(C)C)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O MZPMUGOGQIVILU-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973436P | 2014-04-01 | 2014-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161364A1 true PE20161364A1 (es) | 2016-12-25 |
Family
ID=52815058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001895A PE20161364A1 (es) | 2014-04-01 | 2015-03-18 | CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150274721A1 (enExample) |
| EP (1) | EP3126361B1 (enExample) |
| JP (1) | JP6643247B2 (enExample) |
| KR (1) | KR101886945B1 (enExample) |
| CN (1) | CN106211770B (enExample) |
| AP (1) | AP2016009465A0 (enExample) |
| AR (1) | AR099874A1 (enExample) |
| AU (1) | AU2015242330B2 (enExample) |
| BR (1) | BR112016022519A8 (enExample) |
| CA (1) | CA2944308A1 (enExample) |
| CL (1) | CL2016002422A1 (enExample) |
| CR (1) | CR20160454A (enExample) |
| CU (1) | CU20160140A7 (enExample) |
| DK (1) | DK3126361T3 (enExample) |
| DO (1) | DOP2016000266A (enExample) |
| EA (1) | EA031419B1 (enExample) |
| EC (1) | ECSP16078289A (enExample) |
| ES (1) | ES2759277T3 (enExample) |
| IL (1) | IL248154B (enExample) |
| MD (1) | MD20160102A2 (enExample) |
| MX (1) | MX369074B (enExample) |
| NI (1) | NI201600149A (enExample) |
| PE (1) | PE20161364A1 (enExample) |
| PH (1) | PH12016501864A1 (enExample) |
| SG (1) | SG11201607465UA (enExample) |
| TW (1) | TWI568733B (enExample) |
| UY (1) | UY36054A (enExample) |
| WO (1) | WO2015150957A1 (enExample) |
| ZA (1) | ZA201606252B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| JP6628805B2 (ja) * | 2015-02-03 | 2020-01-15 | ファイザー・インク | 新規シクロプロパベンゾフラニルピリドピラジンジオン |
| CN106580997B (zh) * | 2016-12-09 | 2018-01-19 | 张田 | 一种治疗先兆流产的药物组合物 |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| WO2020053654A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| CN110907542A (zh) * | 2018-09-17 | 2020-03-24 | 复旦大学 | 一种液质联用检测唾液中司来吉兰及其代谢物的方法 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN113543852A (zh) | 2019-03-06 | 2021-10-22 | 第一三共株式会社 | 吡咯并吡唑衍生物 |
| CN114667285B (zh) | 2019-09-26 | 2025-08-08 | 诺华股份有限公司 | 抗病毒吡唑并吡啶酮化合物 |
| JP2025535295A (ja) | 2022-10-18 | 2025-10-24 | ファイザー・インク | パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子 |
| WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| CN1177616C (zh) | 1997-04-09 | 2004-12-01 | 曼德塞特生物制药公司 | 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法 |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| AU3976402A (en) | 2000-11-03 | 2002-06-03 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| MXPA04008364A (es) * | 2002-02-28 | 2005-07-26 | Sanofi Aventis | Derivados de 2-piridinil y 2-pirimidinil-6, 7, 8, 9-tetrahidropirmido [1,2-a] pirimidin-4-ona substituidos por heteroarilo. |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| PL377769A1 (pl) | 2002-10-09 | 2006-02-20 | Rinat Neuroscience Corp. | Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| EP1881985B1 (en) | 2005-05-12 | 2010-12-29 | Pfizer, Inc. | Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| CN101454320B (zh) | 2006-04-21 | 2012-12-19 | 辉瑞产品公司 | 吡啶并[3，4-b]吡嗪酮 |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| CA2741126A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic m1 receptor positive allosteric modulators |
| JP5767393B2 (ja) * | 2011-03-31 | 2015-08-19 | ファイザー・インク | 新規二環式ピリジノン |
| JP6106745B2 (ja) * | 2012-05-16 | 2017-04-05 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体 |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014111457A1 (en) * | 2013-01-17 | 2014-07-24 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| JP6425717B2 (ja) * | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
-
2015
- 2015-03-18 EP EP15714951.9A patent/EP3126361B1/en active Active
- 2015-03-18 CR CR20160454A patent/CR20160454A/es unknown
- 2015-03-18 AU AU2015242330A patent/AU2015242330B2/en not_active Ceased
- 2015-03-18 DK DK15714951.9T patent/DK3126361T3/da active
- 2015-03-18 SG SG11201607465UA patent/SG11201607465UA/en unknown
- 2015-03-18 CA CA2944308A patent/CA2944308A1/en not_active Withdrawn
- 2015-03-18 JP JP2016559879A patent/JP6643247B2/ja not_active Expired - Fee Related
- 2015-03-18 KR KR1020167030135A patent/KR101886945B1/ko not_active Expired - Fee Related
- 2015-03-18 BR BR112016022519A patent/BR112016022519A8/pt not_active IP Right Cessation
- 2015-03-18 PE PE2016001895A patent/PE20161364A1/es not_active Application Discontinuation
- 2015-03-18 WO PCT/IB2015/051988 patent/WO2015150957A1/en not_active Ceased
- 2015-03-18 MX MX2016012904A patent/MX369074B/es active IP Right Grant
- 2015-03-18 ES ES15714951T patent/ES2759277T3/es active Active
- 2015-03-18 AP AP2016009465A patent/AP2016009465A0/en unknown
- 2015-03-18 MD MDA20160102A patent/MD20160102A2/ro not_active Application Discontinuation
- 2015-03-18 CN CN201580018466.7A patent/CN106211770B/zh not_active Expired - Fee Related
- 2015-03-18 EA EA201600619A patent/EA031419B1/ru not_active IP Right Cessation
- 2015-03-27 AR ARP150100922A patent/AR099874A1/es unknown
- 2015-03-27 UY UY0001036054A patent/UY36054A/es not_active Application Discontinuation
- 2015-03-27 US US14/670,746 patent/US20150274721A1/en not_active Abandoned
- 2015-03-31 TW TW104110551A patent/TWI568733B/zh not_active IP Right Cessation
-
2016
- 2016-09-09 ZA ZA2016/06252A patent/ZA201606252B/en unknown
- 2016-09-22 PH PH12016501864A patent/PH12016501864A1/en unknown
- 2016-09-22 CU CUP2016000140A patent/CU20160140A7/es unknown
- 2016-09-27 CL CL2016002422A patent/CL2016002422A1/es unknown
- 2016-09-29 DO DO2016000266A patent/DOP2016000266A/es unknown
- 2016-09-29 NI NI201600149A patent/NI201600149A/es unknown
- 2016-09-29 IL IL248154A patent/IL248154B/en active IP Right Grant
- 2016-09-30 EC ECIEPI201678289A patent/ECSP16078289A/es unknown
-
2017
- 2017-02-24 US US15/441,882 patent/US20170166566A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161364A1 (es) | CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20170128A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| PE20141557A1 (es) | Derivado de pirazoloquinolina | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| MX383823B (es) | Macrociclos de diarilo quirales y usos de los mismo. | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
| PE20170011A1 (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| PE20161021A1 (es) | Derivados heterociclicos biciclicos como inhibidores de bromodominio | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| PE20170501A1 (es) | Un procedimiento que comprende compuestos que administran a un sujeto infectado con neisseria gonorrhoeae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |